Molecular pathology and potential therapeutic targets in soft-tissue sarcoma

References

• CancerStats Monograph 2004. Toms JR (Ed.). Cancer Research UK, London, UK (2004).
   Google Scholar
• World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK, Mertens F (Eds). IARC Press, Lyon, France (2002).
   Google Scholar
• Trojani M, Contesso G, Coindre JM et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int. J. Cancer33, 37–42 (1984).
   PubMed Web of Science ®Google Scholar
• Coindre JM, Trojani M, Contesso G et al. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer58(2), 306–309 (1986).
   PubMed Web of Science ®Google Scholar
• Guillou L, Coindre JM, Bonichon F et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J. Clin. Oncol.15(1), 350–362 (1997).
   PubMed Web of Science ®Google Scholar
• Delaney TF, Yang JC, Glatstein E. Adjuvant therapy for adult patients with soft tissue sarcomas. Oncology5, 105–118 (1991).
   PubMedGoogle Scholar
• Clasby R, Tilling K, Smith MA, Fletcher CDM. Variable management of soft tissue sarcomas: regional audit with implications for specialist care. Br. J. Surg.84, 1692–1696 (1997).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Tepper J, Glatstein E et al. The treatment of soft tissue sarcomas of the extremities: prospective randomised evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann. Surg.196, 305–315 (1982).
   PubMed Web of Science ®Google Scholar
• Suit HD, Mankin HJ, Wood WC et al. Treatment of the patient with stage M0 soft tissue sarcoma. J. Clin. Oncol.6(5), 854–862 (1988).
   PubMed Web of Science ®Google Scholar
• Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet350, 1647–1654 (1997).
   PubMed Web of Science ®Google Scholar
• Gasco M, Crook T. p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resist. Updat.6, 323–328 (2003).
   PubMed Web of Science ®Google Scholar
• Coley HM, Verrill MW, Gregson SE, Odell DE, Fisher C, Judson IR. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur. J. Cancer36(7), 881–888 (2000).
   PubMed Web of Science ®Google Scholar
• Mocellin S, Rossi CR, Brandes A, Nitti D. Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat. Rev.32, 9–27 (2006).
   PubMed Web of Science ®Google Scholar
• Malkin D, Li FP, Strong LC et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science,250, 1233–1238 (1990).
   PubMed Web of Science ®Google Scholar
• Li FP, Fraumeni JF. Soft tissue sarcomas, breast cancer and other neoplasms. A familial syndrome? Ann. Intern. Med.71, 747–752 (1969).
   PubMed Web of Science ®Google Scholar
• Li FP, Fraumeni JF, Mulvihill JJ et al. A cancer family syndrome in twenty four kindreds. Cancer Res.48, 5358–5362 (1988).
   PubMed Web of Science ®Google Scholar
• Sanchez-Garcia I. Consequences of chromosomal abnormalities in tumor development. Ann. Rev. Genet.31, 429–453 (1997).
   PubMed Web of Science ®Google Scholar
• Hogendoorn PCW, Collin F, Daugaard S et al. Changing concepts in the pethological basis of soft tissue and bone sarcoma treatment. Eur. J. Cancer40, 1644–1654 (2004).
   PubMed Web of Science ®Google Scholar
• Guillou L, Benhattar J, Bonichon F et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J. Clin. Oncol.22(20), 4040–4050 (2004).
   PubMed Web of Science ®Google Scholar
• Nilsson M, Meza-Zepeda LA, Mertens F, Forus A, Myklebost O, Mandahl N. Amplification of chromosome 1 sequences in lipomatous tumours and other sarcomas. Int. J. Cancer109, 363–369 (2004).
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y et al. Gain-of-Function mutations of c-kit in human gastrointestinal stromal tumours. Science279(5350), 577–580 (1988).
   Google Scholar
• Nakanishi H, Myoui A, Ochi T, Aozasa K. P-glycoprotein expression in soft-tissue sarcomas. J. Cancer Res. Clin. Oncol.123(6), 352–356 (1997).
   PubMed Web of Science ®Google Scholar
• Serra M, Scotlandi K, Manara MC et al. Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities. Cytotechnology19(3), 253–256 (1996).
   PubMedGoogle Scholar
• Hoffmann J, Schmidt-Peter P, Hansch W et al. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas. Clin. Cancer Res.5, 2198–2204 (1999).
   PubMedGoogle Scholar
• Jimenez RE, Zalupski MM, Frank JJ, Du W, Ryan JR, Lucas DR. Multidrug resistance phenotype in high grade soft tissue sarcomas. Cancer86(6), 976–981 (1999).
   PubMedGoogle Scholar
• Nielsen TO, West RB, Linn SC et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet359, 1301–1307 (2002).
   PubMed Web of Science ®Google Scholar
• Ren B, Yu YP, Jing L et al. Gene expression analysis of human soft tissue leiomyosarcomas. Hum. Pathol.34(6), 549–558 (2003).
   PubMedGoogle Scholar
• Allander SV, Illei PB, Chen Y et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2 and ELF3 with epithelial differentiation. Am. J. Pathol.161(5), 1587–1595 (2002).
   PubMed Web of Science ®Google Scholar
• Nuciforo PG, Pellegrini C, Fasani R et al. Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Hum. Pathol.34(7), 639–645 (2003).
   PubMed Web of Science ®Google Scholar
• Barbashini V, Benevenia J, Aviv H et al. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathological study of 19 cases. J. Res. Clin. Oncol.128(11), 610–616 (2002).
   PubMedGoogle Scholar
• Olsen RJ, Lydiatt WM, Koepsell SA et al. C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck. Head Neck27(10), 883–892 (2005).
   PubMed Web of Science ®Google Scholar
• Sapi Z, Papai Z, Hruska A, Antal I, Bodo M, Orosz Z. Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma. Pathol. Oncol. Res.11(3), 133–138 (2005).
   PubMedGoogle Scholar
• Thomas DG, Giordano TJ, Sanders D et al. Expression of receptor tyrosine kinases, epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer103(4), 830–838 (2005).
   PubMed Web of Science ®Google Scholar
• Terry J, Lubieniecka JM, Kwan W, Liu S, Nielsen TO. Hsp 90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin. Cancer Res.11(15), 5631–5638 (2005).
   PubMed Web of Science ®Google Scholar
• Hollstein M, Rice K, Greenblatt MS et al. Database of p53 gene somatic mutations in human tumours and cell lines. Nucleic Acids Res.22, 3551–3555 (1994).
   PubMed Web of Science ®Google Scholar
• Yoo J, Lee HK, Kang CS, Park WS, Lee JY, Shim SI. p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch. Pathol. Lab. Med.121(4), 395–399 (1997).
   PubMedGoogle Scholar
• Lowe SW, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science266, 807–810 (1994).
   PubMed Web of Science ®Google Scholar
• Schmitt CA, Lowe SW. Apoptosis is critical for drug response in vivo. Drug Resist. Updat.4, 132–134 (2001).
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell108, 153–164 (2002).
   PubMed Web of Science ®Google Scholar
• Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutations on resistance of cultured cells to chemotherapy. Oncogene18, 477–485 (1999).
   PubMed Web of Science ®Google Scholar
• Geisler S, Lonning PE, Aas T et al. Influence of TP53 gene alterations and c-erb-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res.61, 2505–2512 (2001).
   PubMed Web of Science ®Google Scholar
• Rahko E, Blanco G, Soini Y, Bloigu R, Jukkola A. A mutant TP53 gene status is associated with a poor prognosis and anthracycline resistance in breast cancer. Eur. J. Cancer39, 447–453 (2003).
   PubMedGoogle Scholar
• Wu X, Bayle H, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev.7, 1126–1132 (1993).
   PubMed Web of Science ®Google Scholar
• Bartel F, Meye A, Wurl P et al. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 RNA, is associated with prognosis in soft tissue sarcoma. Int. J. Cancer95, 168–175 (2001).
   PubMed Web of Science ®Google Scholar
• Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res.26(15), 3453–3459 (1998).
   PubMed Web of Science ®Google Scholar
• Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta1378(2), 115–177 (1998).
   PubMed Web of Science ®Google Scholar
• Silva J, Dominguez G, Silva JM et al. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene20, 4586–4590 (2001).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Watanabe T, Klangby U et al.p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol.11, 159–168 (2001).
   PubMed Web of Science ®Google Scholar
• Pomerantz J, Schreiber-Agus N, Liegeois L et al. The INK4a tumour supressor gene product, p19ARF, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell92, 713–723 (1998).
   PubMed Web of Science ®Google Scholar
• Honda R, Yasuda H. Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of MDM2 for tumour supressor p53. EMBO J.18, 22–27 (1999).
   PubMed Web of Science ®Google Scholar
• Weber JD, Kuo M-L, Bothner B et al. Cooperative signals governing ARF-Mdm2 interaction and nucleolar localisation of the complex. Mol. Cell Biol.20, 2517–2528 (2000).
   PubMed Web of Science ®Google Scholar
• Lopez-Guerrero JA, Pellin A, Noguera R, Carda C, Llombart-Bosch A. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumours. Lab. Invest.81(6), 803–814 (2001).
   PubMed Web of Science ®Google Scholar
• Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. Analysis of the p16INK4, P14ARF, P15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet. Cytogenet.120, 91–98 (2000).
   PubMed Web of Science ®Google Scholar
• Orlow I, Drobnjak M, Zhang ZF et al. Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival. J. Natl Cancer Inst.91(1), 73–79 (1999).
   PubMedGoogle Scholar
• Roth JA, Nguyen D, Lawerence DD et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med.2, 985–991 (1996).
   PubMed Web of Science ®Google Scholar
• Hupp TR. Regulation of p53 protein function through alterations in protein-folding pathways. Cell. Mol. Life Sci.55, 88–95 (1999).
   PubMed Web of Science ®Google Scholar
• Bykov VJ, Selivanova G, Wiman KG. Small molecules that reactivate mutant p53. Eur. J. Cancer39, 1828–1834 (2003).
   PubMed Web of Science ®Google Scholar
• Roth J, Lenz-Bauer C, Contente A et al. Reactivation of mutant p53 by a one-hybrid adaptor protein. Cancer Res.63, 3904–3908 (2003).
   PubMed Web of Science ®Google Scholar
• Makower D, Rozenblit A, Kaufman H et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumours with correlative p53 studies. Clin. Cancer Res.9, 693–702 (2003).
   PubMed Web of Science ®Google Scholar
• Galanis E, Okuno SH, Nascimento AG et al. Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Therapy12(5), 437–445 (2005).
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B et al.In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science303, 844–848 (2004).
   PubMed Web of Science ®Google Scholar
• Tovar C, Rosinski J, Filipovic Z et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl Acad. Sci. USA7(103), 1659–1660 (2006).
   Google Scholar
• Debeic-Rychter M, Dumez H, Judson I et al. Use of c-KIT.PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer40, 689–695 (2004).
   PubMedGoogle Scholar
• Verweij J, van Oosterom A, Blay JY et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group Phase II study. Eur. J. Cancer39, 2006–2011 (2003).
   PubMed Web of Science ®Google Scholar
• Prenen H, Cools J, Mentens N et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumour mutants refractory to imatinib mesylate. Clin. Cancer Res.12(8), 2622–2627 (2006).
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom A, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet368(9544), 1329–1338 (2006).
   PubMed Web of Science ®Google Scholar
• Zucman J, Melot T, Desmaze C et al. Combinatorial generation of variable fusion proteins in the ewing family of tumours. EMBO J.12, 4481–4487 (1993).
   PubMed Web of Science ®Google Scholar
• Turc-Carel C, Aurias A, Mugneret F et al. Chromosomes in Ewings Sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet. Cytogenet.32(2), 229–238 (1988).
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Yoshida K, Handa M et al. Fusion of an ETS-family gene, E1AF to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosomes Cancer15, 115–121 (1996).
   PubMed Web of Science ®Google Scholar
• Peter M, Couturier J, Pacquement H et al. A new member of the ETS family fused to EWS in Ewing tumours. Oncogene14, 1159–1164 (1997).
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Tschernyavsky SJ, Woodruff JM, Jungbluth AA, Brennan M, Ladanyi M. Detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases. J. Mol. Diagn.4(1), 44–52 (2002).
   PubMed Web of Science ®Google Scholar
• Labelle Y, Zucman J, Stenman G et al. Oncogeneic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum. Mol. Genet.4, 2219–2226 (1995).
   PubMed Web of Science ®Google Scholar
• Ladanyi M, Gerald W. Fusion of the EWS and ET1 genes in the desmoplastic small round cell tumour. Cancer Res.54, 2837–2840 (1994).
   PubMed Web of Science ®Google Scholar
• Waters BL, Panagopoulos I, Allen EF. Genetic characterization of angiomatoid fibrous histiocytoma identifies fusion of the FUS and ATF-1 genes induced by the chromosomal translocation involving bands 12q13 and 16p11. Cancer Genet. Cytogenet.121, 109–116 (2000).
   PubMedGoogle Scholar
• Raddaoui E, Donner LR, Panagopoulos I. Fusion of the FUS and ATF-1 genes in a large, deep-seated angiomatoid fibrous histiocytoma. Diagn. Mol. Pathol.11, 157–162 (2002).
   PubMedGoogle Scholar
• Ladanyi M, Lui MY, Antonescu CR et al. The der(17)t(X;17)(p11;q25)of human alveolar soft part sarcoma fuses the TFE transcription factor gene to ASPL, a novel gene at 17q25. Oncogene20, 48–57 (2001).
   PubMed Web of Science ®Google Scholar
• Fitzgerald JC, Scherr AM, Barr FG. Structural analysis of PAX7 rearrangements in alveolar rhadbomyosarcoma. Cancer Genet. Cytogenet.117(1), 37–40 (2000).
   PubMedGoogle Scholar
• Sirvent N, Maire G, Pedetour F. Genetics of dermatofibrosarcoma protuberans family of tumours: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer37, 1–19 (2003).
   PubMed Web of Science ®Google Scholar
• Knezevich SR, McFadden DE, Tao W, Linm JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nature Genetics18, 184–187 (1998).
   PubMed Web of Science ®Google Scholar
• Koontz JI, Soreng AL, Nucci M et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumours. Proc. Natl Acad. Sci. USA98(11), 6348–6353 (2001).
   PubMed Web of Science ®Google Scholar